ProMIS Neurosciences Inc (PMN)

[xr_biotech_consult]

We've met all our milestones.

TLSR: Can you describe the recent increase in ProMIS stock, which has nearly doubled over the last month or so?

EG: We think the increase is about reaching a critical mass, if you like. The program's been moving forward as per plan. We've met all our milestones. That's just good performance and that's important, especially in this market because biotech is risky. It's not the same as fermenting yogurt, right? Not to be glib, but human disease is complex.